Therapy Areas: Respiratory
Partner Therapeutics' zenocutuzumab-zbco granted US FDA Orphan Drug Designation for treatment of cholangiocarcinoma
6 February 2026 - Biotechnology company Partner Therapeutics Inc (PTx) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zenocutuzumab-z...
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
4 February 2026 - Cizzle Biotechnology Holdings plc (LSE: CIZ), a UK-based developer of diagnostic tests for early-stage cancer, announce on Wednesday that it has been granted patent protection in Can...
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
3 February 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) and British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) announced on Tuesday that ...
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
29 January 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Thursday that the US Food and Drug Administration (FDA) has accepted its Biologics License Appli...
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
28 January 2026 - French medical imaging company Guerbet (Euronext Paris:GBT) announced on Tuesday that it has received approval from the European Commission for a new indication in children from birt...
United Therapeutics reports positive phase 1 data for bioengineered liver in acute liver failure
26 January 2026 - Pharmaceutical company United Therapeutics Corporation (Nasdaq: UTHR) on Monday reported positive results from a phase 1 clinical trial of miroliverELAP, an external liver assist pro...